ALKternate: A Proof of Concept Study in ALK-Rearranged NSCLC Alternating Lorlatinib With Crizotinib After Disease Progression

被引：0
|
作者：
Itchins, M. [1 ]
Liang, S. [1 ]
Brown, C. [2 ]
Solomon, B. [3 ]
Pavlakis, N. [1 ]
机构：
[1] Royal North Shore Hosp, Med Oncol, St Leonards, NSW, Australia
[2] Univ Sydney, Nhmrc Clin Trials Ctr, Camperdown, NSW, Australia
[3] Peter Maccallum Canc Ctr, Melbourne, Vic, Australia
来源：
JOURNAL OF THORACIC ONCOLOGY | 2021年 / 16卷 / 10期
关键词：
Drug resistance; ALK; Clinical trial;
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
P47.12
引用
收藏
页码：S1101 / S1102
页数：2
相关论文
共 50 条
  • [1] ALKternate: A Proof of Concept Study in ALK-Rearranged NSCLC Alternating Lorlatinib with Crizotinib After Disease Progression
    Itchins, M.
    Hayes, S.
    Hudson, A.
    Howell, V.
    Tan, S. W. D.
    Clarke, S.
    Solomon, B.
    Pavlakis, N.
    JOURNAL OF THORACIC ONCOLOGY, 2019, 14 (10) : S642 - S643
  • [2] ALKTERNATE: A Pilot Study Alternating Lorlatinib with Crizotinib in Patients with ALK plus NSCLC and ALK-inhibitor Resistance
    Itchins, M.
    Liang, S.
    Brown, C.
    Barnes, T.
    Marx, G.
    Chin, V.
    Kao, S.
    Yip, P. Y.
    Mersiades, A. J.
    Nagrial, A.
    Bray, V.
    Peters, G.
    Parakh, S.
    John, T.
    Li, M.
    Li, B. T.
    McKay, M.
    Molloy, M.
    O'Byrne, K.
    Lee, C.
    Gill, A.
    Solomon, B. J.
    Pavlakis, N.
    JOURNAL OF THORACIC ONCOLOGY, 2023, 18 (11) : S351 - S352
  • [3] ALKTERNATE: A Pilot Study Alternating Lorlatinib With Crizotinib in ALK-Positive NSCLC With Prior ALK Inhibitor Resistance
    Itchins, Malinda
    Liang, Shirley
    Brown, Chris
    Barnes, Tristan
    Marx, Gavin
    Chin, Venessa
    Kao, Steven
    Yip, Po Yee
    Mersiades, Antony J.
    Nagrial, Adnan
    Bray, Victoria
    Peters, Geoffrey
    Parakh, Sagun
    Garg, Kavita
    Li, Bob T.
    Mckay, Matthew
    O'Byrne, Kenneth
    John, Thomas
    Gill, Anthony J.
    Molloy, Mark P.
    Solomon, Benjamin J.
    Pavlakis, Nick
    JTO CLINICAL AND RESEARCH REPORTS, 2024, 5 (09):
  • [4] Lorlatinib and Bevacizumab Activity in ALK-Rearranged Lung Cancers After Lorlatinib Progression
    Choudhury, Noura J.
    Young, Robert J.
    Sellitti, Matthew
    Miller, Alexandra
    Drilon, Alexander
    JCO PRECISION ONCOLOGY, 2020, 4 : 1333 - 1338
  • [5] A new option for crizotinib-resistant ALK-rearranged NSCLC
    不详
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 2014, 95 (06) : 573 - 573
  • [6] Treatment beyond disease progression: ALK inhibitors in ALK-rearranged advanced NSCLC
    Leighl, N. B.
    Kuo, J.
    Pavel, A.
    Prescilla, M.
    Shepherd, F. A.
    Liu, G.
    Bradbury, P.
    Moskovits, M.
    ANNALS OF ONCOLOGY, 2017, 28
  • [7] ALECTINIB IS ACTIVE IN CRIZOTINIB-RESISTANT ALK-REARRANGED NSCLC
    Gadgeel, S. M.
    Gandhi, L.
    Riely, G. J.
    Chiappori, A. A.
    West, H. L.
    Azada, M. C.
    CANCER DISCOVERY, 2014, 4 (10) : 1113 - 1113
  • [8] Mechanisms of Acquired Resistance to the ALK Inhibitor Lorlatinib in ALK-Rearranged NSCLC Cell Lines
    Madsen, A.
    Jakobsen, K.
    Demuth, C.
    Sorensen, B.
    JOURNAL OF THORACIC ONCOLOGY, 2017, 12 (11) : S2255 - S2255
  • [9] Response to Crizotinib Re-administration After Progression on Lorlatinib in a Patient With ALK-rearranged Non-small-cell Lung Cancer
    Sakakibara-Konishi, Jun
    Kitai, Hidenori
    Ikezawa, Yasuyuki
    Hatanaka, Yutaka
    Sasaki, Takaaki
    Yoshida, Ryohei
    Chiba, Shinichi
    Matsumoto, Shingo
    Goto, Koichi
    Mizugaki, Hidenori
    Shinagawa, Naofumi
    CLINICAL LUNG CANCER, 2019, 20 (05) : E555 - E559
  • [10] LOREALAUS: LOrlatinib REAL-World AUStralian Experience in Advanced ALK-Rearranged NSCLC
    Alexander, Marliese
    Wei, Joe
    Parakh, Sagun
    John, Thomas
    Kao, Steven
    Nagrial, Adnan
    Bowyer, Samantha
    Warburton, Lydia
    Moore, Melissa
    Hughes, Brett G. M.
    Clay, Timothy D.
    Pavlakis, Nick
    Solomon, Benjamin J.
    Itchins, Malinda
    JTO CLINICAL AND RESEARCH REPORTS, 2023, 4 (04):
12345